NCT00714519撤回2 期
A Phase II Feasibility Study of Xenaderm® Ointment Exploring Design Issues for Phase III Efficacy in Partial-Thickness Wounds
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- Healthpoint
- 主要终点
- Complete Wound Closure
研究概览
简要总结
This study will assess if a clinical trial regarding healing of partial thickness wounds can be executed in nursing homes.
详细描述
This study will test the efficacy of Xenaderm® vs. vehicle on the healing of partial thickness wounds caused by pressure, moisture and friction.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Triple (Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide written informed consent, which consists of reading, signing and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information. If the subject is unable to read or sign the informed consent, or unable to comprehend the information provided in the consent process, a legal guardian, decision making proxy, or next of kin must provide written consent, and if possible, subject must verbally assent to receiving an experimental treatment for their wound.
- •Are at least 18 years of age.
- •Are expected to remain in the Nursing Home for the duration of the study (22 days).
- •Have one or more partial-thickness wounds (including wounds with excoriation, erosion or denuded skin, or ulceration to subcutaneous fat, but with no fascia, muscle, tendon or bone visible) on the trunk or proximal extremity (arm above the elbow, leg above the knee) which
- •have been present for at least 2 days but less than 6 weeks;
- •measure greater than or equal to 2 and less than or equal to40 cm2 in total denuded area; and,
- •are connected by areas of erythema (for multiple wounds).
- •Are capable of maintaining an adequate nutritional intake during the study.
- •Are in an acceptable state of health and nutrition with pre-albumin levels of greater than or equal to 15 mg/dl (0.015g/l), serum albumin greater than or equal to 3.0 g/dl (30g/l), alkaline phosphatase greater than or equal to the lower limit of normal, and have no abnormal laboratory values that, in the opinion of the Medical Supervisor, place the subject at risk for the study.
排除标准
- •Have more than 64 cm2 of total denuded wound area, including target and non-target wounds.
- •Have a full-thickness wound within 4 cm of any target wound.
- •Have clinical evidence of bacterial or fungal infection of the target wound.
- •Have target wound(s) that involves tunneling, sinus tracks, shear injury, arterial occlusive disease or bony prominence or joint with the exception that target wounds may be over dorsal spinous processes, coccyx, ischial tuberosities or sacroiliac joints (but may not be full thickness).
- •Are moribund, or has a severe burn, immunodeficiency disorder, hematologic disorder, metastatic malignancy or uncontrolled diabetes mellitus.
- •Are known to have acrodermatitis enteropathica (zinc deficiency).
- •Are being treated with systemic steroids, immunosuppressive agents, radiation or chemotherapy.
- •Have been treated with enzymatic debridement to the target wound(s) within 2 days prior to enrollment.
- •Have a known sensitivity to ingredients of Xenaderm Ointment.
- •Are using or have used another investigational agent (not including devices such as hearing aids, pace makers, etc.) within 30 days prior to Visit 1.
研究组 & 干预措施
1
Experimental
干预措施: Xenaderm® Ointment (Drug)
2
Placebo Comparator
干预措施: Placebo Comparator (Drug)
结局指标
主要结局
Complete Wound Closure
时间窗: 21 days
次要结局
- Adverse Events(21 days)
研究者
相似试验
已完成
2 期
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma GangrenosumPyoderma GangrenosumNCT01965613Janssen Research & Development, LLC10
已完成
2 期
Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot UlcersChronic Diabetic Foot UlcerNCT00709514Oneness Biotech Co., Ltd.41
尚未招募
不适用
Novel Donor Site Dressing (Product X)BurnsNCT06163742Hamilton Health Sciences Corporation40
已完成
1 期
A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton SyndromeNetherton SyndromeNCT05211830Sixera Pharma9
已完成
2 期
Lidocaine Patches Prior to Intravenous InsertionNeed for Intravenous CatheterNCT00552695Stony Brook University45